Menu

Top Stories

Published on Thursday, July 11, 2019

Two years have passed since the liver transplant surgery that saved Jude Ward’s life

Two years have passed since the liver transplant surgery that saved Jude Ward’s life

Almost two years have passed since Nicole and Josef Ward’s son, Jude, had a liver transplant due to Alpha-1 Antitrypsin Deficiency (Alpha-1). You can read that story by clicking here.

Most people diagnosed with Alpha-1 don’t exhibit symptoms until they reach adulthood, when underproduction of the alpha-1 antitrypsin protein leads to complications in the lungs and eventual lung disease, according to the Children’s Organ Transplant Association (COTA). However, Jude was producing an abnormal form of the protein, which started pooling in his liver, damaging it.

By 22 months of age, Jude was experiencing serious liver problems. In December 2016, he was rushed to an emergency room, where doctors said Jude would need a life-saving liver transplant to survive.

The family quickly got Jude onto the waiting list for a liver transplant at a hospital in their native Florida, did seemingly endless research on liver disorders in children, and eventually joined COTA.

The Wards, who now live on the joint base, ended up having better luck seeking a transplant at the Children’s Hospital of Philadelphia.

“On July 6, 2017, at 7 am, we got our first call that the hospital had a possible liver match for Jude,” Nicole Ward recalled. “We spent the entire day at the hospital doing pre-op tests on Jude and making him fast only to find out at 9:30 pm that upon retrieval of the liver it was determined not to be the best match for our Jude. We went back to our temporary transplant home broken more than ever but still clinging to a little hope that Jude’s call would come soon,” she added.

A couple of weeks later, Jude was back in the hospital for complications of his liver disease. By July 19, doctors had found a match for him, and the next day, he had a successful surgery.

“We were very relieved but could not quite let ourselves believe this was the one until he was wheeled into surgery about midnight that same night,” Ward said.

In the months leading up to the surgery, the Wards said Jude’s body was failing him. He could only take in food through a feeding tube, he needed infusions to get rid of excess fluid in his stomach, he was tired all the time but could not sleep comfortably, and he would get bruises and sores that didn’t heal.

Though Jude, now 4, had a successful transplant, it still impacts his life in small ways, as he must make frequent visits to the transplant center for lab work, checkups and adjustments to his immunosuppression medications, his family said.

While the family temporarily lived in Philadelphia at the Gift of Life Family House, COTA was able to raise more than $60,000 for COTA in honor of Jude and his medical expenses.

The family also fears they might go through a similar journey all over again. Their daughter Lucie, born last July, has the same deficiency. She is now in the process of receiving regular lab work to check her liver enzymes and regular ultrasounds.

“We do not know where things are headed with Lucie and a liver transplant, but her doctors are keeping a close eye on her,” Ward said.

“Life after transplant is a balance of enjoying life but also being mindful of keeping Jude healthy. The biggest blessing our family has received is the blessing of perspective,” she finished.

Sources: Burlington County Times, Children’s Organ Transplant Association

Photo courtesy of the Children’s Organ Transplant Association.


Print

Alpha-1 Hero Walk raises funds and awareness for Alpha-1

Thursday, May 23, 2019
The 9th Annual Alpha-1 Hero Walk took place on May 4th, in Richmond, VA, where 75 attendees walked to raise awareness and funds for Alpha-1 Antitrypsin Deficiency (Alpha-1) research and related programs, exceeding $11,000. Pamela VanScoy, Walk...
Divider

Alpha-1 Foundation celebrates the 2019 research grants

Tuesday, May 21, 2019
The Alpha-1 Foundation (A1F) hosted a reception on Monday, May 20, 2019, to honor the newly awarded research grant recipients, where 158 guests joined at the Perot Museum in Dallas, Texas, in conjunction with the 2019 American Thoracic...
Divider

New method could help find potential treatments for rare diseases

Monday, May 20, 2019
Finding treatments for rare diseases is difficult: because they affect such a small number of people, research funding and other resources may be limited. Even if researchers are interested in studying a rare disease, the methods for testing...
Divider

Celebration of Life 2019: “Alpha-1 Derby: Betting on the cure”

Friday, May 10, 2019
On Monday, April 29th, the Alpha-1 Foundation welcomed friends, family, physicians, researchers, and industry partners to the 19th Annual Celebration of Life, the Foundation’s signature fundraising event in Miami Beach, Florida. The event is...
Divider

Funding for NIH increased after House Appropriations Committee approves funding bill

Friday, May 10, 2019
The House Appropriations Committee approved the fiscal year 2020 Labor, Health and Human Services, Education, and Related Agencies bill, on Wednesday, May 8, 2019. The legislation includes funding for programs within the Departments of Labor,...
Divider

NORD releases principles to lower the cost of prescription drugs

Wednesday, May 8, 2019
The National Organization for Rare Disorders (NORD), which represents the 25-30 million Americans living with rare disorders, including Alpha-1 Antitrypsin Deficiency (Alpha-1), announced its development of key drug pricing principles,...
Divider

Alpha-1 Foundation attends Coalition of Patient Advocacy Groups (CPAG) Meeting

Tuesday, May 7, 2019
The Alpha-1 community was well represented as the Alpha-1 Foundation attended the Coalition of Patient Advocacy Groups (CPAG) Meeting, in Rockville, MD, on April 30, 2019. Photo (left to right): Jamie Sullivan, COPD Foundation; David Fernandez,...
Divider

FDA approves new, larger vial sizes for Alpha-1 augmentation therapy

Thursday, April 25, 2019
The U.S. Food and Drug Administration (FDA) has approved single-vial dosing (4-gram and 5-gram vial sizes) for ZEMAIRA® [Alpha1-Proteinase Inhibitor] for augmentation therapy, the current treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1)...
Divider

Alpha-1 Foundation co-sponsors congressional reception for the NHLBI Division of Lung Diseases

Wednesday, April 17, 2019
On April 9, 2019, the Alpha-1 Foundation was proud to be a co-sponsor of the congressional reception to celebrate the 50th anniversary of the Division of Lung Diseases of the National Heart, Lung and Blood Institute (NHLBI), an institute of the...
Divider

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Thursday, April 11, 2019
On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by...
Divider

International Research Conference on Alpha-1 Antitrypsin & Alpha-1 Global Patient Congress kick-off

Wednesday, April 3, 2019
Alphas, physicians, and researchers are joining together in Dubrovnik, Croatia to begin the highly anticipated 4th International Research Conference on Alpha-1 Antitrypsin and 7th Alpha-1 Global Patient Congress. With a rich history of...
Divider

Alpha Jonathan Maidment goes back to the Pacific Crest Trail

Monday, April 1, 2019
Determined, driven, ready, and focused are some of the words that best describe Jonathan Maidment, 24, an Alpha from Connecticut who is passionate about hiking and helping the Alpha-1 community.  Jonathan is ready and looking forward to...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive